Effect of diabetes mellitus on Melioidosis patients
Not Applicable
- Conditions
- Health Condition 1: A499- Bacterial infection, unspecified
- Registration Number
- CTRI/2022/07/043709
- Lead Sponsor
- ICMR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Melioidosis:
1)Patients diagnosed with melioidosis only
2)No past history of receiving any melioidosis treatment
3)Above 18yrs of age
4)Patients with or without COVID-19 co-Infection
Diabetes mellitus only:
1) Patients diagnosed with type-II diabetes mellitus
2) Patients on diabetes mellitus treatment
Healthy controls:
1) Individuals with no history of diabetes mellitus
2)Above 18yrs of age
Exclusion Criteria
Melioidosis:
1) Patients with previous history of melioidosis
2) Patients with other co-infection
3) Relapse cases of melioidosis
4) Below 18yrs of age
Diabetes mellitus only:
1) Patients with acute infection
Healthy controls:
1) Individuals with no evidence of any active or chronic disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The effect of diabetes mellitus in Melioidosis patients with respect to its immunometabolismTimepoint: Outcomes will be measured at 0, 3 and 6 months
- Secondary Outcome Measures
Name Time Method As the aim of the study involves understanding the effect of DM on cellular immunometabolic response of the melioidosis, it will offer insights into immunopathogenesis that might aid in identifying potential candidates for development of a vaccine and adjuvant therapies for people with DM for the susceptible population in the endemic areas or in identifying drug targets that may provide protection under diabetic co-morbidities.Timepoint: 10 years